ERBB2 and endometrial serous adenocarcinoma: However, trastuzumab increased PFS and OS when combined with carboplatin/paclitaxel in patients with HER2/Neu-positive advanced or recurrent uterine-serous-carcinoma (USC) [177], and trastuzumab appears to be safe and exhibit a manageable toxicity profile in patients with HER2/Neu-positive USC, both in combination with chemotherapy and as a single-agent maintenance [178].